12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

More documents

Recommendations

Info

Rekommandation Eksperimentel. Unge patienter ( or = 60 years old with relapsed or refractory B- cell lymphoma. J Clin Oncol. 2007; 25: 1396-402. Neumeister P, Hoefler G, Beham-Schmid C, et al. Complete remission of generalized relapsed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type of the gastrointestinal tract after high-dose chemotherapy and autologous peripheral stem cell transplantation. Ann Hematol 2000;79:703-5. 76
Rezvani AR, Storer B, Maris M et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and trans<strong>for</strong>med indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26: 211-17. 77
Page 1 and 2:
Rekommandationer for knoglemarvstra
Page 3 and 4:
Vævstyper og terminologi Ved valg
Page 5 and 6:
3.valg: 9/10 allel forligelig ubesl
Page 7 and 8:
Petersdorf EW et al: Major-histocom
Page 9 and 10:
Sygdomsspecifikke overvejelser & kr
Page 11 and 12:
Non myeloablativ stamcelletransplan
Page 13 and 14:
Akutte Leukæmier ALL hos voksne AL
Page 15 and 16:
En metaanalyse af 7 studier, hvor a
Page 17 and 18:
Højrisikofaktorer • Fænotype: N
Page 19 and 20:
Kemoterapi Hoelzer, D.F (1993). The
Page 21 and 22:
unrelated transplant in first compl
Page 23 and 24:
ALL hos børn 5% blaster i knoglema
Page 25 and 26: i det nordamerikanske register, af
Page 27 and 28: Risikogrupper for AML i 1. CR Lavri
Page 29 and 30: Autolog KMT Litteraturen på områd
Page 31 and 32: Gale, R.P., Horowitz, M.M., Weiner,
Page 33 and 34: myelogenous leukemia in first compl
Page 35 and 36: AML hos børn
Page 37 and 38: Eapen M, Rubinstein P, Zhang MJ, Ca
Page 39 and 40: Point Parameter 0 0.5 1 1.5 2 Blast
Page 41 and 42: *) Specielt i denne gruppe gælder
Page 43 and 44: Kantarjian H, O'Brien S, Cortes J,
Page 45 and 46: Scott BL, Sandmaier BM, Storer B, M
Page 47 and 48: tiltagende. Patienter med RC og hø
Page 49 and 50: Donor leukocyte infusion after hema
Page 51 and 52: � Konstitutionelle symptomer, for
Page 53 and 54: Responskriterier ved CML Responstyp
Page 55 and 56: patienter, som statistisk set vil h
Page 57 and 58: Mauro,M.J. (2006) Defining and mana
Page 59 and 60: LYMFOMER Lymfoblastært lymfom Lymf
Page 61 and 62: Der er ingen data, der indicerer at
Page 63 and 64: BURKITT'S LYMFOM Senest revideret:
Page 65 and 66: Hoelzer D, Ludwig W-D, , Thiel E et
Page 67 and 68: Der er ikke indikation for autolog
Page 69 and 70: sequential chemotherapy in poor-ris
Page 71 and 72: af immunosuppressiv beh. og DLI og
Page 73 and 74: following high-dose sequential chem
Page 75: Marginal Zone Lymfom Senest revider
Page 79 and 80: eskriver også sammenhæng mellem i
Page 81 and 82: HCT ved refraktær sygdom (Verdonck
Page 83 and 84: transplantation for lymphoprolifera
Page 85 and 86: Perifere T-Celle Lymfomer Senest re
Page 87 and 88: Referencer: Evens AM, Gartenhaus RB
Page 89 and 90: Hodgkin Lymfom (HL) Senest revidere
Page 91 and 92: Patienter med progressiv sygdom ell
Page 93 and 94: Transplant, 12,172-183. Anderlini,P
Page 95 and 96: Allogen KMT 1. HLA-identisk søsken
Page 97 and 98: Referencer Definition Bacigalupo A,
Page 99 and 100: Paroxysmal Nocturn Haemoglobinuri,
Page 101 and 102: Autolog transplantation Myelomatose
Page 103 and 104: Cavo M, Tosi P, Zagmani E, Cellini
Page 105 and 106: Myelofibrose Idiopatisk myelofibros
Page 107 and 108: Introduktion Retransplantation af b
Page 109 and 110: Den samlede konklusion kunne være,
Page 111 and 112: Thalassæmier Senest revideret nove
Page 113 and 114: thalassæmifri overlevelse på 66%
Page 115 and 116: Kronisk granulomatøs sygdom Senest
show all

12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Create successful ePaper yourself

Delete template?

Save as template?